# Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults

> **NCT06507605** · PHASE1 · COMPLETED · sponsor: **Serum Institute of India Pvt. Ltd.** · enrollment: 240 (actual)

## Conditions studied

- Prevention of Malaria Transmission and Clinical Malaria

## Interventions

- **BIOLOGICAL:** R21
- **BIOLOGICAL:** Pfs230D1-CRM197
- **BIOLOGICAL:** Pfs230D1-EPA
- **OTHER:** Matrix-M

## Key facts

- **NCT ID:** NCT06507605
- **Lead sponsor:** Serum Institute of India Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-30
- **Primary completion:** 2026-01-24
- **Final completion:** 2026-01-24
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06507605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06507605, "Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06507605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*